Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

4.3K
The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
4.3K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

78.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

8.8K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating the global inventory of deprioritized clinical-stage drug development programs: Toward a market for shelved assets.

Drug discovery today·2026
Same author

NF1 and SPRED1/2 cooperate through RAS-MAPK-independent functions.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Imaging features and the role of image-guided biopsy for assessment of premalignant versus malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Neuro-oncology practice·2026
Same author

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS<sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibition.

bioRxiv : the preprint server for biology·2026
Same author

Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass.

The Biochemical journal·2026
Same author

Dashboard Knee: Injury Mechanisms, Diagnostic Challenges, and Treatment Outcomes.

Cureus·2026

Related Experiment Video

Updated: Jul 28, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.0K

RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging

Steven D Rhodes1, Frank McCormick2, Ross L Cagan3

  • 1Division of Hematology-Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA; Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.

The Journal of Investigative Dermatology
|May 28, 2023
PubMed
Summary

Cutaneous neurofibromas (cNFs), common in neurofibromatosis type 1, lack effective treatments. Understanding RAS signaling in cNF development is key to finding new therapies for these skin tumors.

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K

Related Experiment Videos

Last Updated: Jul 28, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.0K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K

Area of Science:

  • Oncology
  • Genetics
  • Dermatology

Background:

  • Cutaneous neurofibromas (cNFs) are the most common tumor in neurofibromatosis type 1 (NF1).
  • Hundreds to thousands of cNFs can develop, with no current preventive or therapeutic options.
  • NF1 is a genetic rasopathy impacting RAS signaling pathways.

Purpose of the Study:

  • To review the current understanding of RAS signaling in cNF pathogenesis.
  • To highlight therapeutic development strategies for cNF treatment.
  • To identify knowledge gaps and future research directions for cNF therapies.

Main Methods:

  • Literature review of studies on RAS signaling in cNF.
  • Analysis of research on therapeutic targets and drug development for cNFs.
  • Synthesis of current knowledge on cNF biology and NF1 genetics.

Main Results:

  • RAS signaling pathways are critically involved in cNF initiation, growth, and maintenance.
  • Dysregulation of specific RAS effectors contributes to cNF development.
  • Several therapeutic strategies targeting RAS pathway components are under investigation.

Conclusions:

  • A deeper understanding of RAS signaling in cNF pathogenesis is essential for developing effective treatments.
  • Targeting RAS effector pathways holds promise for future cNF therapies.
  • Further research is needed to translate preclinical findings into clinical interventions for cNFs.